Mizuho Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Uy Ear maintains a Buy rating on Arcutis Biotherapeutics (NASDAQ:ARQT) and raises the price target from $17 to $18.
May 15, 2024 | 11:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho analyst Uy Ear maintains a Buy rating on Arcutis Biotherapeutics and raises the price target from $17 to $18.
The Buy rating and increased price target from a reputable analyst at Mizuho is likely to positively influence investor sentiment and drive short-term price appreciation for ARQT.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100